Influence of microbial stimulation on hypergammaglobulinemia and autoantibody production in pristane-induced lupus

Clinical Immunology and Immunopathology

Volumn 86, Issue 3, 1998, Pages 271-279

  Hamilton, Kimberly J ^a   Satoh, Minoru ^a   Swartz, John ^a   Richards, Hanno B ^a   Reeves, Westley H ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Animal models; Autoantibodies; Hypergammaglobulinemia; Pristane; Systemic lupus erythematosus

Indexed keywords

DNA ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; PRISTANE; RIBONUCLEOPROTEIN ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE ACTIVATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HYPERGAMMAGLOBULINEMIA; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0032030864     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1006/clin.1997.4481     Document Type: Article

References (60)

1. Avigan J., Milne G. W. A., Highet R. J. The occurrence of pristane and phytane in man and animals. Biochim. Biophys. Acta. 144:1967;127-131.
2. Castle L., Kelly M., Gilbert J. Migration of mineral hydrocarbons into foods. 2. Polystyrene, ABS, and waxed paperboard containers for dairy products. Food Additives Contaminants. 10:1993;167-174.
3. Boitnott J. K., Margolis S. Mineral oil in human tissues. I. Detection of saturated hydrocarbons using thin-layer chromatography. Bull. Johns Hopkins Hosp. 118:1966;402-413.
4. Wanless I. R., Geddie W. R. Mineral oil lipogramulomata in liver and spleen: A study of 465 autopsies. Arch. Pathol. Lab. Med. 109:1985;283-286.
5. Firriolo J. M., Morris C. F., Trimmer G. W., Twitty L. D., Smith J. H., Freeman J. J. Comparative 90-day feeding study with low-viscosity white mineral oil in Fischer-344 and Sprague-Dawley-derived CRL:CD rats. Toxicol. Pathol. 23:1995;26-33.
6. Potter M., Boyce C. R. Induction of plasma-cell neoplasms in strain BALB/c mice with mineral oil and mineral oil adjuvants. Nature. 193:1962;1086-1087.
7. Anderson P. N., Potter M. Induction of plasma cell tumours in BALB/c mice with 2,6,10,14-tetramethylpentadecane (pristane). Nature. 222:1969;994-995.
8. Potter M., MacCardle R. C. Histology of developing plasma cell neoplasia induced by mineral oil in BALB/c mice. J. Natl. Cancer Inst. 33:1964;497-515.
9. Potter M., Wax J. S., Anderson A. O., Nordan R. P. Inhibition of plasmacytoma development in BALB/c mice by indomethacin. J. Exp. Med. 161:1985;996-1012.
10. Stryker W. A. Absorption of liquid petrolatum ("mineral oil") from the intestine. Arch. Pathol. 31:1941;670-692.
11. Dincsoy H. P., Weesner R. E., MacGee J. Lipogranulomas in non-fatty human livers: A mineral oil induced environmental disease. Am. J. Clin. Pathol. 78:1982;35-41.
12. Cruickshank B. Follicular (mineral oil) lipidosis. I. Epidemiologic studies of involvement of the spleen. Hum. Pathol. 15:1984;724-730.
13. Spickard A. Exogenous lipoid pneumonia. Arch. Intern. Med. 154:1994;686-692.
14. Kumagai Y., Shiokawa Y., Medsger T. A. J., Rodnan G. P. Clinical spectrum of connective tissue disease after cosmetic surgery. Observations on eighteen patients and a review of the Japanese literature. Arthritis Rheum. 27:1984;1-12.
15. Satoh M., Reeves W. H. Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane. J. Exp. Med. 180:1994;2341-2346.
16. Satoh M., Treadwell E. L., Reeves W. H. Pristane induces high titers of anti-Su and anti-nRNP/Sm autoantibodies in BALB/c mice. Quantitation by antigen capture ELISAs based on monospecific human autoimmune sera. J. Immunol. Methods. 182:1995;51-62.
17. Satoh M., Kumar A., Kanwar Y. S., Reeves W. H. Antinuclear antibody production and immune complex glomerulonephritis in BALB/c mice treated with pristane. Proc. Natl. Acad. Sci. USA. 92:1995;10934-10938.
18. Wooley P. H., Seibold J. R., Whalen J. D., Chapdelaine J. M. Pristane-induced arthritis. The immunologic and genetic features of an experimental murine model of autoimmune disease. Arthritis Rheum. 32:1989;1022-1030.
19. Alarcon-Segovia D., Cabral A. R. Autoantibodies in systemic lupus erythematosus. Curr. Opin. Rheumatol. 8:1996;403-407.
20. Chai S. K., Mantovani L., Kasaian M. T., Casali P. Natural autoantibodies. Adv. Exp. Med. Biol. 347:1994;147-159.
21. Dziarski R. Autoimmunity: Polyclonal activation or antigen induction. Immunol. Today. 9:1988;340-342.
22. Lymberi P., Blancher A., Clavas P., Avrameas S. Natural autoantibodies in nude and normal outbred (Swiss) and inbred (BALB/c) mice. J. Autoimmun. 2:1989;283-295.
23. Budman D. R., Merchant E. B., Steinberg A. D., Doft B., Gershwin M. E., Lizzio E., Reeves J. P. Increased spontaneous activity of antibody-forming cells in the peripheral blood of patients with active SLE. Arthritis Rheum. 20:1977;829-833.
24. Sakane T., Suzuki N., Takada S., Ueda Y., Murakawa Y., Tsuchida T., Yamauchi Y., Kishimoto T. B cell hyperactivity and its relation to distinct clinical features and the degree of disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 31:1988;80-87.
25. Klinman D. M., Steinberg A. D. Systemic autoimmune disease arises from polyclonal B cell activation. J. Exp. Med. 165:1987;1755-1760.
26. Klinman D. Polyclonal B cell activation in lupus-prone mice precedes and predicts the development of autoimmune disease. J. Clin. Invest. 86:1990;1249-1254.
27. Izui S., McConahey P. J., Dixon F. J. Increased spontaneous polyclonal activation of B lymphocytes in mice with spontaneous autoimmune disease. J. Immunol. 121:1978;2213-2219.
28. Shlomchik M., Mascelli M., Shan H., Radic M. Z., Pisetsky D., Marshak-Rothstein A., Weigert M. Anti-DNA antibodies from autoimmune mice arise by clonal expansion and somatic mutation. J. Exp. Med. 171:1990;265-298.
29. Wofsy D., Seaman W. E. Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J. Exp. Med. 161:1985;378-391.
30. Santoro T. J., Portanova J. P., Kotzin B. L. The contribution of L3T4+ T cells to lymphoproliferation and autoantibody production in MRL-lpr/lpr mice. J. Exp. Med. 167:1988;1713-1718.
31. Maciel R. J. Standard curve fitting in immunodiagnostics: A primer. J. Clin. Immunoassay. 8:1985;98-106.
32. Hahn B. H. Animal models of systemic lupus erythematosus. Dubois' Lupus Erythematosus. 1996;Williams & Wilkins, Baltimore. p. 339-380.
33. Theofilopoulos A. N., Dixon F. J. Murine models of systemic lupus erythematosus. Adv. Immunol. 37:1985;269-390.
34. Sadlack B., Merz H., Schorle H., Schimpl A., Feller A. C., Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell. 75:1993;253-261.
35. Kühn R., Löhler J., Rennick D., Rajewsky K., Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 75:1993;263-274.
36. Murakami M., Nakajima K., Yamazaki K., Muraguchi T., Serikawa T., Honjo T. Effects of breeding environments on generation and activation of autoreactive B-1 cells in anti-red blood cell autoantibody transgenic mice. J. Exp. Med. 185:1997;791-794.
37. Klinman D. M., Eisenberg R. A., Steinberg A. D. Development of the autoimmune B cell repertoire in MRL-lpr/lpr mice. J. Immunol. 144:1990;506-511.
38. Satoh M., Hamilton K. J., Ajmani A. K., Dong X., Wang J., Kanwar Y. S., Reeves W. H. Autoantibodies to ribosomal P antigens with immune complex glomerulonephritis in SJL mice treated with pristane. J. Immunol. 157:1996;3200-3206.
39. Hess E. Drug-related lupus. N. Engl. J. Med. 318:1988;1460-1462.
40. Burlingame R. W., Rubin R. L. Drug-induced anti-histone autoantibodies display two patterns of reactivity with substructures of chromatin. J. Clin. Invest. 88:1991;680-690.
41. Foucar E., Erickson D. G., Tung K. S. Glomerulonephritis in procainamide induced lupus erythematosus: Report of a case and review of the literature. J. Clin. Lab. Immunol. 2:1979;79-84.
42. +T cells and IFN-γ production in plasmacytoma-susceptible BALB/cAnPt mice. Cell. Immunol. 146:1993;157-170.
43. Byrd L. G., McDonald A. H., Gold L. G., Potter M. Specific pathogen-free BALB/cAn mice are refractory to plasmacytoma induction by pristane. J. Immunol. 147:1991;3632-3637.
44. Merino R., Iwamoto M., Fossati L., Izui S. Polyclonal B cell activation arises from different mechanisms in lupus-prone (NZB × NZW)F1 and MRL/MpJ-lpr/lprmice. J. Immunol. 151:1993;6509-6516.
45. Coutinho A., Moller G. Thymus-independent B-cell induction and paralysis. Adv. Immunol. 21:1975;114-236.
46. Mond J. J., Vos Q., Lees A., Snapper C. M. T cell independent antigens. Curr. Opin. Immunol. 7:1995;349-354.
47. Steinberg E. B., Santoro T. J., Chused T. M., Smathers P. A., Steinberg A. D. Studies of congenic MRL-lpr/lpr.xidmice. J. Immunol. 131:1983;2789-2795.
48. Reininger L., Radaszkiewicz T., Kosco M., Melchers F., Rolink A. G. Development of autoimmune disease in SCID mice populated with long-term "in vitro" proliferating (NZB × NZW)F1 pre-B cells. J. Exp. Med. 176:1992;1343-1353.
49. Lehmann D., Ben-Nun A. Bacterial agents protect against autoimmune disease. I. Mice pre-exposed toBordetella pertussisorMycobacterium tuberculosisare highly refractory to induction of experimental autoimmune encephalomyelitis. J. Autoimmun. 5:1992;675-690.
50. Thompson S. J., Butcher P. D., Patel V. K. R., Rook G. A. W., Stanford J., van der Zee R., Elson C. J. Modulation of pristane-induced arthritis by mycobacterial antigens. Autoimmunity. 11:1991;35-43.
51. Like A. A., Guberski D. L., Butler L. Influence of environmental viral agents on frequency and tempo of diabetes mellitus in BB/Wor rats. Diabetes. 40:1991;259-262.
52. Penhale W. J., Young P. R. The influence of the normal microbial flora on the susceptibility of rats to experimental autoimmune thyroiditis. Clin. Exp. Immunol. 72:1988;288-292.
53. Murakami M., Tsubata T., Shinkura R., Nisitani S., Okamoto M., Yoshioka H., Usui T., Miyawaki S., Honjo T. Oral administration of lipopolysaccharides activates B-1 cells in the peritoneal cavity and lamina propria of the gut and induces autoimmune symptoms in an autoantibody transgenic mouse. J. Exp. Med. 180:1994;111-121.
54. Thompson S. J., Elson C. J. Susceptibility to pristane-induced arthritis is altered with changes in bowel flora. Immunol. Lett. 36:1993;227-231.
55. Gianani R., Sarvetnick N. Viruses, cytokines, antigens, and autoimmunity. Proc. Natl. Acad. Sci. USA. 93:1996;2257-2259.
56. Shacter E., Arzadon G. K., Williams J. Elevation of interleukin-6 in response to a chronic inflammatory stimulus in mice: Inhibition by indomethacin. Blood. 80:1992;194-202.
57. Hirano T., Taga T., Yasukawa K., Nakajima K., Nakano N., Takatsuki F., Shimizu M., Murashima A., Tsunasawa S., Sakiyama F., Kishimoto T. Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. Proc. Natl. Acad. Sci. USA. 84:1987;228-231.
58. Suematsu S., Matsuda T., Aozasa K., Akira S., Nakano N., Ohno S., Miyazaki K., Hirano T., Kishimoto T. IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc. Natl. Acad. Sci. USA. 86:1989;7547-7551.
59. Horii Y., Muraguchi A., Iwano M., Matsuda T., Hirayama T., Yamada H., Fujii Y., Dohi K., Ishikawa H., Ohmoto Y., Yoshizaki K., Hirano T., Kishimoto T. Involvement of IL-6 in mesangial proliferative glomerulonephritis. J. Immunol. 143:1989;3949-3955.
60. Nagafuchi H., Suzuki N., Mizushima Y., Sakane T. Constitutive expression of IL-6 receptors and their role in the excessive B cell function in patients with systemic lupus erythematosus. J. Immunol. 151:1993;6525-6534.